sellWeak10b5-1 plan
Richard A Colvin sold $176 of BLUE
Chief Medical Officer at bluebird bio, Inc.. 19 shares at an average of $9.24, traded Jan 6, 2025, filed Jan 8, 2025.
Warning score
0Value
$176
19 shares
Holdings after
8,257
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$176 at market
- 0Share of holdings soldSold 0.2% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-25-000270, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 6, 2025 | SOpen-market sale Common Stock10b5-1 | -19 | $9.24 | $176 | 8,257 | Jan 8, 2025 |
Related signals
Other insiders at bluebird bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $2,289 584 shares | -7% | |
| 3Weak | bluebird bio, Inc. | Thomas J Klima See Remarks | $1,960 500 shares | -6% | |
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $473 64 shares | -1% | |
| 3Weak | bluebird bio, Inc. | Thomas J Klima See Remarks | $902 122 shares | -1% | |
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $1,178 2,824 shares | -2% | |
| 13Weak | bluebird bio, Inc. | Andrew Obenshain President and CEO | $405 971 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.